Orm-6151

Advanced Malignant Tumors

Bristol-Myers SquibbPhase 1Active

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 95/ 100

Competitive context

1411 Active assets in the Advanced Malignant Tumors cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Orm-6151 is also rated in:

small cell lung carcinomaDormant

B

Indicative ·

60 / 100

Solid TumoursDormant

CC

Indicative ·

45 / 100

myelodysplastic syndromeDormant

C

Indicative ·

39 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.